Drug intelligence / Profile preview

CRS-207 + cisplatin + pemetrexed

Development stage: Phase 1
Lead developer: Novartis
Modality: Vaccines & Immunotherapeutics, Small Molecules
Administration: Intravenous

Overview

CRS-207 + cisplatin + pemetrexed is a combination therapy that pairs a live-attenuated Listeria monocytogenes-based immunotherapy vaccine with standard chemotherapy for the treatment of malignant pleural mesothelioma (MPM). CRS-207 is engineered to express mesothelin, a tumor-associated antigen highly expressed in MPM. The vaccine works by inducing antitumor immune responses and increasing susceptibility of neoplastic cells to immune-mediated killing. When combined with the chemotherapy agents pemetrexed and cisplatin, this regimen has shown promising clinical responses in MPM patients, with significant changes observed in the local tumor microenvironment.

Other names: Immunotherapy plus chemotherapyCRS-207 with Chemotherapy in Malignant Pleural MesotheliomaCRS207 with Chemotherapy in Malignant Pleural MesotheliomaCRS 207 with Chemotherapy in Malignant Pleural MesotheliomaImmunotherapy with cyclophosphamide plus chemotherapy

Targets

DNAMesothelinTS (Thymidylate synthase)

Beyond the preview

Go deeper on CRS-207 + cisplatin + pemetrexed.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CRS-207 + cisplatin + pemetrexed.